186 related articles for article (PubMed ID: 37170264)
1. Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition.
Saha A; Zhao S; Kindall A; Wilder C; Friedman CA; Clark R; Georgiou G; Stone E; Kidane D; DiGiovanni J
J Exp Clin Cancer Res; 2023 May; 42(1):119. PubMed ID: 37170264
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer.
Saha A; Zhao S; Chen Z; Georgiou G; Stone E; Kidane D; DiGiovanni J
Mol Ther; 2021 Feb; 29(2):775-787. PubMed ID: 33091613
[TBL] [Abstract][Full Text] [Related]
3. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
Cramer SL; Saha A; Liu J; Tadi S; Tiziani S; Yan W; Triplett K; Lamb C; Alters SE; Rowlinson S; Zhang YJ; Keating MJ; Huang P; DiGiovanni J; Georgiou G; Stone E
Nat Med; 2017 Jan; 23(1):120-127. PubMed ID: 27869804
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth.
Kshattry S; Saha A; Gries P; Tiziani S; Stone E; Georgiou G; DiGiovanni J
NPJ Precis Oncol; 2019; 3():16. PubMed ID: 31231686
[TBL] [Abstract][Full Text] [Related]
5. Cyst(e)inase-Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer.
Kerimoglu B; Lamb C; McPherson RD; Ergen E; Stone EM; Ooi A
Mol Cancer Ther; 2022 Mar; 21(3):419-426. PubMed ID: 35086957
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
7. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
8. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
9. Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress.
Boldogh I; Roy G; Lee MS; Bacsi A; Hazra TK; Bhakat KK; Das GC; Mitra S
Toxicology; 2003 Nov; 193(1-2):137-52. PubMed ID: 14599773
[TBL] [Abstract][Full Text] [Related]
10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
11. Selenocystine induces oxidative-mediated DNA damage via impairing homologous recombination repair of DNA double-strand breaks in human hepatoma cells.
Wahyuni EA; Yii CY; Liang HL; Luo YH; Yang SH; Wu PY; Hsu WL; Nien CY; Chen SC
Chem Biol Interact; 2022 Sep; 365():110046. PubMed ID: 35863474
[TBL] [Abstract][Full Text] [Related]
12. CD8
Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
[TBL] [Abstract][Full Text] [Related]
13. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
[TBL] [Abstract][Full Text] [Related]
14. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.
Liu X; Gao R; Dong Y; Gao L; Zhao Y; Zhao L; Zhao X; Zhang H
BMC Cancer; 2010 Aug; 10():418. PubMed ID: 20698994
[TBL] [Abstract][Full Text] [Related]
15. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
16. hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
Adams MN; Croft LV; Urquhart A; Saleem MAM; Rockstroh A; Duijf PHG; Thomas PB; Ferguson GP; Najib IM; Shah ET; Bolderson E; Nagaraj S; Williams ED; Nelson CC; O'Byrne KJ; Richard DJ
Prostate; 2023 May; 83(7):628-640. PubMed ID: 36811381
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
Lu S; Dong Z
PLoS One; 2019; 14(10):e0223894. PubMed ID: 31600334
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
